CoChat

Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study

Open access

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Many commercially available glucagon products for treatment of severe hypoglycaemia require cumbersome reconstitution and potentially intimidating injection during an emergency. Nasal glucagon (NG) is a novel drug-device combination product consisting of a single-use dosing device that delivers glucagon dry powder through nasal administration. The present study assessed whether 3 mg NG was non-inferior to 1 mg intramuscular glucagon (IMG) in adults with type 1 diabetes. METHODS: This randomised, open-label, two-period, crossover trial was conducted at two clinical sites. Hypoglycaemia (plasma glucose [PG] target of < 3.3 mmol/l (60 mg/dl) was induced by an intravenous insulin infusion. Glucagon preparations were given by study staff. Treatment success was defined as an increase in PG to ≥ 3.9 mmol/l (70 mg/dl) or an increase of ≥ 1.1 mmol/l (20 mg/dl) from the PG nadir within 30 min of receiving glucagon. RESULTS: Of the 66 participants included in the primary efficacy analysis who received both NG and IMG, 100% achieved treatment success, thus demonstrating non-inferiority of NG to IMG. All participants achieved treatment success within 25 min with the mean time to treatment success of 11.4 min (NG) and 9.9 min (IMG). No serious adverse events occurred. Forty-eight treatment-emergent adverse events (TEAEs) occurred after NG and 51 after IMG. Most TEAEs were mild and transient. CONCLUSION: Nasal glucagon was as efficacious and well tolerated as IMG for the treatment of insulin-induced hypoglycaemia in adults and will be as useful as IMG as a rescue treatment for severe hypoglycaemia. TRIAL REGISTRATION: NCT03339453, ClinicalTrials.gov.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-020-00845-7

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Kaplan-Meier curve for the time to treatment success (an increase in PG to ≥ 3.9 mmol/l [70 mg/dl] or a PG increase of ≥ 1.1 mmol/l [20 mg/dl] from nadir) within 30 min following 3 mg nasal glucagon and 1 mg GlucaGen® treatment in participants who completed all dosing visits. Red line = 3 mg nasal glucagon (N = 68); black line = 1 mg intramuscular glucagon (N = 69). IM intra-muscular, PG plasma glucose
Fig. 1 Kaplan-Meier curve for the time to treatment success (an increase in PG to ≥ 3.9 mmol/l [70 mg/dl] or a PG increase of ≥ 1.1 mmol/l [20 mg/dl] from nadir) within 30 min following 3 mg nasal glucagon and 1 mg GlucaGen® treatment in participants who completed all dosing visits. Red line = 3 mg nasal glucagon (N = 68); black line = 1 mg intramuscular glucagon (N = 69). IM intra-muscular, PG plasma glucoseCC BY-NC · PubMed Central
Fig. 2 a Arithmetic mean (± SD) profile of plasma glucose concentration after a single dose of 3 mg NG or 1 mg IMG. Red circles and line = 3 mg nasal glucagon (N = 68; baseline mean PG = 3.2 mmol/l; SD = 0.3); white circle and black line = 1 mg intramuscular glucagon (N = 69; baseline mean PG = 3.2 mmol/l; SD = 0.3). b Change from baseline plasma glucagon concentration (±SD) following single doses of 3 mg nasal glucagon or 1 mg GlucaGen. Red circles and line = 3 mg nasal glucagon (N = 68); white circle and black line = 1 mg intramuscular glucagon (N = 69). min minutes, SD standard deviation
Fig. 2 a Arithmetic mean (± SD) profile of plasma glucose concentration after a single dose of 3 mg NG or 1 mg IMG. Red circles and line = 3 mg nasal glucagon (N = 68; baseline mean PG = 3.2 mmol/l; SD = 0.3); white circle and black line = 1 mg intramuscular glucagon (N = 69; baseline mean PG = 3.2 mmol/l; SD = 0.3). b Change from baseline plasma glucagon concentration (±SD) following single doses of 3 mg nasal glucagon or 1 mg GlucaGen. Red circles and line = 3 mg nasal glucagon (N = 68); white circle and black line = 1 mg intramuscular glucagon (N = 69). min minutes, SD standard deviationCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 1

  1. Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998;17(22):2635–50. · DOI · Paper page

Cited by

See all 33

Metadata

Authors
Suico, J. G., Hövelmann, U., Zhang, S., Shen, T., Bergman, B., Sherr, J., Zijlstra, E., Frier, B. M., & Plum-Mörschel, L.
Affiliations
  • Eli Lilly (United States) (US)
  • Profil Institute for Metabolic Research (DE)
  • Yale University (US)
  • The Queen's Medical Research Institute (GB)
Corresponding author
Suico, Jeffrey G.
Venue
Diabetes Therapy
Published
2020-06-08
Volume
11
Issue
7
Pages
1591-1603
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W3033451567
Cited by
32
References
13
Citations by year
2026: 1 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 6 · 2021: 4
FWCI
3.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
Keywords
nasal glucagon, type 1 diabetes, severe hypoglycemia, insulin-induced hypoglycemia, drug-device combination products, non-inferiority, treatment success, adverse events

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. https://app.cochat.ai/papers/10.1007/s13300-020-00845-7
The paper
Suico, J. G., Hövelmann, U., Zhang, S., Shen, T., Bergman, B., Sherr, J., Zijlstra, E., Frier, B. M., & Plum-Mörschel, L. (2020). Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. Diabetes Therapy. https://doi.org/10.1007/s13300-020-00845-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.